Technical Analysis for RTRX - Retrophin, Inc.

Grade Last Price % Change Price Change
grade C 23.96 4.77% 1.09
RTRX closed up 4.77 percent on Monday, March 18, 2019, on 1.36 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical RTRX trend table...

Date Alert Name Type % Chg
Mar 18 Pocket Pivot Bullish Swing Setup 0.00%
Mar 18 Upper Bollinger Band Walk Strength 0.00%
Mar 18 Above Upper BB Strength 0.00%
Mar 18 Upper Bollinger Band Touch Strength 0.00%
Mar 15 Pocket Pivot Bullish Swing Setup 4.77%
Mar 15 Upper Bollinger Band Walk Strength 4.77%
Mar 15 Upper Bollinger Band Touch Strength 4.77%
Mar 14 Upper Bollinger Band Walk Strength 6.49%
Mar 14 Inside Day Range Contraction 6.49%
Mar 14 Upper Bollinger Band Touch Strength 6.49%

Older signals for RTRX ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Retrophin, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of orphan drugs for the treatment of rare and life-threatening diseases. The company develops treatments for Focal Segmental Glomerulosclerosis (FSGS), Pantothenate Kinase-Associated Neurodegeneration (PKAN), Duchenne Muscular Dystrophy and other catastrophic diseases. Its products include RE-021, a small molecule angiotensin receptor blocker and selective endothelin receptor antagonist for the treatment of FSGS; and RE-024, a drug that restores the disruption in the biochemical Coenzyme A pathway caused by the non-functioning PANK2 encoded enzyme. The company also develops RE-001, a recombinant fusion protein that substitutes the dystrophin that is lacking in DMD patients; and RE-003, an investigational agent for spinal muscular atrophy. The company was founded in 2011 and is based in New York, New York.
Medicine Biopharmaceutical Medical Genetics Kidney Diseases Muscular Dystrophy Spinal Muscular Atrophy Duchenne Muscular Dystrophy Genetic Genealogy Dystrophy Channelopathies
Is RTRX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 33.0
52 Week Low 19.77
Average Volume 342,903
200-Day Moving Average 25.5817
50-Day Moving Average 21.9082
20-Day Moving Average 21.844
10-Day Moving Average 22.122
Average True Range 0.8871
ADX 24.26
+DI 34.8664
-DI 12.3919
Chandelier Exit (Long, 3 ATRs ) 21.6037
Chandelier Exit (Short, 3 ATRs ) 23.0013
Upper Bollinger Band 23.5226
Lower Bollinger Band 20.1654
Percent B (%b) 1.13
BandWidth 15.36898
MACD Line 0.3306
MACD Signal Line 0.0857
MACD Histogram 0.2449
Fundamentals Value
Market Cap 919.71 Million
Num Shares 38.4 Million
EPS -1.84
Price-to-Earnings (P/E) Ratio -13.02
Price-to-Sales 6.36
Price-to-Book 3.08
PEG Ratio -1.05
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 26.02
Resistance 3 (R3) 25.86 25.03 25.67
Resistance 2 (R2) 25.03 24.50 25.10 25.56
Resistance 1 (R1) 24.49 24.18 24.76 24.65 25.44
Pivot Point 23.66 23.66 23.79 23.73 23.66
Support 1 (S1) 23.12 23.13 23.39 23.28 22.48
Support 2 (S2) 22.29 22.81 22.36 22.36
Support 3 (S3) 21.75 22.29 22.25
Support 4 (S4) 21.91